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http:WHAT THIS PAPER ADDS
The article summarises a meta-analysis of antithrombotic treatment for extra cranial carotid artery dissections
and concludes that there is no clear evidence for one type of treatment over another. In short, medical
treatment lies at the discretion of the treating surgeon.Introduction: Carotid artery dissection is a leading cause of stroke in younger patients, with an associated
prevalence of 2.6e3.0 per 100,000 population. This meta-analysis aims to determine whether in patients
managed medically, treatment with anticoagulants or antiplatelet agents was associated with a better outcome
with respect to mortality, ischaemic stroke, and major bleeding episodes.
Patients and methods: A comprehensive search strategy was employed of the Cochrane Central Register of
Controlled Trials (CENTRAL), MEDLINE (January 1966 to March 2015), and EMBASE (January 1980 to March 2015)
databases. Primary outcomes were death (all causes) or disability. Secondary outcomes were ischaemic stroke,
symptomatic intracranial haemorrhage, and major extracranial haemorrhage during the reported follow-up
period.
Results: No completed randomized trials were found. Comparing antiplatelets with anticoagulants across 38
studies (1,398 patients), there were no signiﬁcant differences in the odds of death (effects size, ES, 0.007,
p ¼ .871), nor in the death and disability comparison or across any secondary outcomes.
Conclusion: There were no randomised trials comparing either anticoagulants or antiplatelets with control, thus
there is no level 1 evidence to support their routine use for the treatment of carotid artery dissection. Also, there
were no randomised trials that directly compared anticoagulants with antiplatelet drugs, and the reported non-
randomised studies did not show any evidence of a signiﬁcant difference between the two.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The incidence of carotid artery dissection (CAD) is quoted
as 2.6e3.0 per 100,000 population,1 although the true
incidence may be higher as many remain undiagnosed.2
CAD is the most common cause of stroke in males un-
der 45 years of age,3 and has an associated mortality ofresponding author. Addenbrooke’s Hospital, Hills Road, Cambridge
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//dx.doi.org/10.1016/j.ejvs.2015.04.034up to 5% with a full resolution occurring in excess of 90%
of cases.4 CAD is associated with trauma, aneurysm, hy-
pertension, and atherosclerosis.5 Presentation can vary
from incidental ﬁndings of asymptomatic disease to ce-
rebrovascular events, regional pain, and Horner’s
syndrome.
Although recent developments in noninvasive imaging
have led to more frequent diagnoses, there is no consensus
or high-level evidence on optimal management. Manage-
ment strategies are aimed predominantly at limiting pro-
gression of dissection, preventing thromboembolic
complications and maintaining cerebral perfusion.1 The
majority of patients are managed by antithrombotic treat-
ment through anticoagulation or antiplatelet therapy,
Acute Extracranial Carotid Artery Dissections 149although endovascular intervention or surgery may be
considered on an individualised basis.1
The aim of this study is to compare anticoagulation and
antiplatelet treatment outcomes including death, ischaemic
stroke, and intra- and extra-cranial haemorrhage in patients
with extracranial carotid artery dissection using meta-
analysis techniques.
METHODS
An electronic search was undertaken using the Cochrane
Central Register of Controlled Trials (CENTRAL), MEDLINE
(January 1966 to March 2015), and EMBASE (January 1980
to March 2015) databases. The search employed the term(s)
“Carotid dissection,” which was combined with each of the
following Boolean operators: “antiplatelet,” “anti-
coagulation,” “extracranial.” Abstracts of the citations
identiﬁed by the search were then scrutinised by two au-
thors to determine eligibility for inclusion in the analysis
(MC, CS). The Cochrane Stroke Group Trials Register was
also searched for relevant studies. Comprehensive searches
were carried out and relevant papers were also interrogated
for additional eligible studies including recent review pa-
pers. The search method adhered to the PRISMA statement
for reporting systematic reviews (Fig. 1).6 Outcome mea-
sures identiﬁed included death from all cause, death and
disability, ischaemic strokes, symptomatic intracranial hae-
morrhage, and major extracranial haemorrhage.Figure 1. StudyAll forms of trials and studies including at least 10 pa-
tients with carotid artery dissection that allowed compari-
sons between antiplatelet therapy and anticoagulation for
the treatment of CAD were deemed eligible for inclusion.
Any study analysing only one form of antithrombotic ther-
apy was excluded. Further exclusion criteria included
studies involving less than 10 patients, review articles,
duplicate data (only the most recent series was included),
and studies where no division was made between carotid
and vertebral artery dissections. Patients with severe
infarction (deﬁned in line with the Modiﬁed Rankin Scale as
severe disability, requiring constant nursing care and
attention, bedridden, incontinent) or with signiﬁcant co-
morbidity that were not given any antithrombotic therapy
were also excluded from the analysis. Data were collected
by two authors (MC, CS) and the quality of the non-
randomised studies was assessed using the Newcastle-
Ottawa Scale (NOS) (Fig. 2). The NOS is primarily formu-
lated by a point allocation system, assigning a maximum of
nine points for the risk of bias in three areas: (i) selection of
study groups (four points), (ii) comparability of groups (two
points), and (iii) outcomes and/or exposure for cohort
studies and case-control studies (two points). Studies
looking at surgical intervention were not included in the
analysis, because of a lack of substantial data.
Information was sought regarding diagnosis, clinical
presentation, and diagnostic ﬁndings. All studies thatselection.
Figure 2. The Newcastle-Ottawa Scale (NOS) for study quality assessment.
150 M.M. Chowdhury et al.reported at least one primary outcome comparing patients
treated with anticoagulation versus those treated with an-
tiplatelet therapy were included. Studies that did not have
follow-up data or studies that had ambiguity surrounding
treatment data were excluded from analysis. There was no
stipulation on the type of imaging modality used to deter-
mine the diagnosis of CAD, which was derived from the
visualisation of ﬁndings consistent with carotid artery
dissection: irregularity of the vessel wall, angiographic string
sign, pseudoaneurysm formation, and double barrel lumen.
Antithrombotic therapy (antiplatelet agent (AP) or anti-
coagulation (AC)) was deﬁned as administration of any
antiplatelet agent (AP, i.e. acetylsalicyclic acid, clopidogrel
dipyridamole) or anticoagulation (AC, oral coumarin or
therapeutic dose heparins). Patients were classiﬁed as being
AP or AC based on their initial treatment modality.Regarding bleeding complications, a clear distinction was
made to assess the ﬁrst antithrombotic agent used, and not
include patients who subsequently went on to receive
thrombolysis as a treatment modality. Any form of surgery
precluded the patient in the formal analysis.Statistical analysis
To estimate treatment effects, data from non-randomised
studies were analysed. The outcome measures of interest
were obtained from studies that were deemed eligible.
Studies that did not have follow-up data or studies that had
ambiguity surrounding treatment data were excluded from
analysis. An arcsine difference was used in the meta-
analysis in conjunction with the Rucker conservative vari-
ance formula.7 The attraction of this method is the
STUDY Antiplatelet Anticoagulation 
Arauz 2006 4/44 0/14 
Ast 1993 0/21 0/30 
Biller 1986 0/5 0/1 
Biousse 1998 0/1 0/3 
Bogousslavsky 1987 0/2 0/21 
Campos 2007 1/6 3/30 
Caso 2004 1/10 0/9 
Chen 1984 0/5 0/1 
Colella 1996 0/2 2/12 
De Bray 1989 0/4 0/14 
Dziewas 2003 0/7 1/71 
Eachempati 1998 0/3 0/5 
Eljamel 1990 0/4 0/4 
Engelter 2000 0/8 1/25 
Friedman 1980 0/1 0/4 
Georgiadis 2009 0/96 0/202 
Gonzales-Portillo 2002 0/5 0/14 
Kaps 1990 0/2 0/4 
Kennedy 2012 0/66 1/30 
Landre 1987 1/3 0/2 
Lepojarvi 1988 0/4 0/7 
Li 1994 0/1 1/4 
Luken 1979 0/2 0/1 
Marx 1987 0/1 0/6 
Metso 2009 0/4 1/140 
Miller-Fisher 1978 0/1 0/2 
Mokri 1986 0/9 0/10 
Miller-Forell 1989 0/1 0/1 
Pieri 2007 0/10 0/14 
Rao 2011 0/54 0/40 
Richaud 1980 1/1 0/5 
Schievink 1990 0/5 0/2 
Sellier 1983 0/13 0/16 
Touze 2003 0/18 2/279 
Trieman 1996 0/6 0/12 
Vanneste 1984 0/1 0/4 
Wahl 2002 0/1 1/7 
Zelenock 1982 0/1 0/1 
TOTAL 8 13 
A B
Figure 3. (A) Comparison of AP and AC: Death from all cause. (B) Breakdown of comparison of AP and AC: Death from all cause.
Acute Extracranial Carotid Artery Dissections 151asymptotically variance-stabilising transformation for the
binomial distribution. Although not frequently used for
meta-analyses, it is a validated analysis method for clinical
data with binary endpoints and should in fact be used when
the event in question is rare.7
RESULTS
A total of 178 papers were retrieved from electronic data-
base searches, as outlined above. Thirty-ﬁve of the 178
papers were duplicates, so were removed from the end
number. Eighty-six of the remaining 143 papers were
obviously irrelevant publications e based primarily on the
title (i.e. intra-cranial carotid, vertebral arteries). A further
analysis of the abstracts meant that a further 19 papers
were excluded. This left 38 papers that fulﬁlled the inclusion
criteria (see Supplemental data).12e49 All studies included in
the analysis were observational case series. In the majority
of studies, treatment decisions were made on an individu-
alised basis and did not follow a prescribed protocol. There
was an overall mean clinical follow-up of 17.7 months
(range 1e72 months).Primary outcomes
Death from all causes. Thirty-eight studies were analysed
with 1,475 patients (428 antiplatelet (AP) and 1,047anticoagulation (AC)) (Fig. 3A, B). A total of 21 (1.42%)
patients had died by the end of the follow-up period. Pa-
tients with severe infarction or with signiﬁcant comorbidity
and therefore not treated with antithrombotic therapy,
equating to 56, were not included in the analysis (separate
from the 1,475 patients). Using the arcsine difference, the
effects size was 0.007 with a 95% CI ranging from 0.095
to 0.081 (p ¼ .871), indicating neither harm nor beneﬁt of
anticoagulation versus antiplatelet with respect to death
during the follow-up period. There was no signiﬁcant het-
erogeneity between the included series (I2 ¼ 0%; T2 ¼ 0%).
Death and disability. Twenty eight studies were analysed
equating to 653 patients (254 AP and 399 AC) (Fig. 4A, B).
Analysis showed there to be no beneﬁt of antiplatelet
therapy when compared to anticoagulation (ES 0.006,
95% CI 0.157 to 0.146; P ¼ 0.940). There was no signiﬁ-
cant heterogeneity between the included series (I2 ¼ 9.9%;
T2 ¼ 0.0155%).
Secondary outcomes
Ischaemic stroke. Thirty-six studies with 1,452 patients (420
AP and 1032 AC) reported on ischaemic strokes at the end
of the follow-up period (Fig. 5A, B). Twenty-four patients
(1.75%) suffered an ischaemic stroke. For 16 of the 24 pa-
tients, data on time of event was available. Ten of the 16
STUDY Antiplatelet Anticoagulation
Arauz 2006 34/44 8/14
Biousse 1998 0/1 0/3
Campos 2007 3/6 11/30
Caso 2004 4/10 3/9
Chen 1984 2/5 0/1
Colella 1996 0/2 2/12
De Bray 1989 0/4 0/14
Eachempati 1998 1/3 1/5
Eljamel 1990 2/4 0/4
Engelter 2000 2/8 5/25
Friedman 1980 0/1 0/4
Kaps 1990 1/2 1/4
Kennedy 2012 0/66 0/30
Landre 1987 1/3 1/2
Lepojarvi 1988 1/4 1/7
Li 1994 0/1 3/4
Luken 1979 0/2 0/1
Marx 1987 0/1 0/6
Metso 2009 0/4 36/140
Miller-Fisher 1978 0/1 0/2
Mokri 1986 0/9 0/10
Pieri 2007 5/10 1/14
Rao 2011 0/54 0/40
Richaud 1980 1/1 2/5
Schievink 1990 0/5 1/2
Vanneste 1984 0/1 0/4
Wahl 2002 1/1 4/7
Zelenock 1982 0/1 0/1
TOTAL 58 80
A
B
Figure 4. (A) Comparison of AP and AC: Death and disability. (B) Breakdown of comparison of AP and AC: Death and disability.
152 M.M. Chowdhury et al.patients developed their stroke within 8 days of treatment
being started. The stroke rate in the anticoagulation group
was 1.74% (18/1,032) and 1.43% (6/420) in the AP group.
The ES of 0.047 (95% CI 0.136 to 0.042, p ¼ .30) indi-
cated no signiﬁcant difference between treatment options.
There was no signiﬁcant heterogeneity between the
included series (I2 ¼ 0%; T2 ¼ 0%).
Symptomatic intracranial haemorrhage. Twenty-seven
studies with 1,075 patients (378 AP and 697 AC) provided
data about symptomatic intracranial haemorrhage strati-
ﬁed on the type of antithrombotic treatment (Fig. 6A, B).
Symptomatic intracranial haemorrhages occurred only in
the AC group and were present in ﬁve of 697 patients
(0.72%). The ES of 0.045 with a 95% CI of 0.142 to
0.052 indicated no signiﬁcant difference between the
treatment options (p ¼ .364). There was no signiﬁcant
heterogeneity between the included series (I2 ¼ 0%;
T2 ¼ 0%).
Major extracranial haemorrhage. Analysis in respect of
major extracranial haemorrhage was based on 14 studies
involving 812 patients (317 AP and 495 AC) (Fig. 7A, B).
Major extracranial haemorrhages occurred only in the AC
group and were present in seven of 495 patients (1.42%).
The ES of 0.058 with a 95% CI of 0.166 to 0.049 indi-
cated no signiﬁcant difference between the treatment op-
tions (p ¼ .289). There was no signiﬁcant heterogeneity
between the included series (I2 ¼ 0%; T2 ¼ 0%).DISCUSSION
CAD is the major cause of ischaemic stroke in young in-
dividuals, but currently there are no randomized trials
available to assess the effects of anticoagulation versus
antiplatelets for such patients. This meta-analysis showed no
differences with regard to outcome or complication rates
when comparing therapeutic anticoagulation with anti-
platelet therapy. Speciﬁcally, there was no signiﬁcant differ-
ence in observedmortality with lowmortality rates observed
when compared with more historical data.8 When deter-
mining both ischaemic and haemorrhagic stroke rate, again
no signiﬁcant differences were seen although the point es-
timate of 1.04 when assessing ischaemic stroke suggests a
potential trend towards a superiority of antiplatelet therapy.
Bleeding-related complications were rare but did occur
exclusively in the AC group of patients and it is likely the small
sample size that prevents a statistical signiﬁcance being seen.
This is in keeping with results seen in other studies.9
The analysis excluded patients who presented with se-
vere infarction or with signiﬁcant comorbidity across the
studies analysed, as no forms of antithrombotic medication
were given and as such did not meet the inclusion criteria.
Therefore, the estimated death rate of this review may not
reﬂect not the entirety of CAD patients but only of patients
who are well enough to receive any kind of antithrombotic
treatment. A series of 55 dissection patients gives a mor-
tality rate over a 3-month period to be 5.5%.10 This is
certainly higher than the calculated risk of 0.081%.
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Campos 2007 0/6 1/30
Caso 2004 1/10 1/9
Chen 1984 0/5 0/1
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Dziewas 2003 0/7 0/71
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TOTAL 6 18
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Figure 5. (A) Comparison of AP and AC: Ischaemic stroke. (B) Breakdown of comparison of AP and AC: Ischaemic stroke.
Acute Extracranial Carotid Artery Dissections 153Furthermore, when assessing the outcome of death or
disability, no obvious superiority between anticoagulation
and antiplatelet therapy was observed. although the narrow
conﬁdence interval (0.157 to 0.146) indicates that any
effect could be smaller.
A further limitation to this analysis was the inadequacy of
the papers to comment on the severity of cerebrovascular
events. This is important as it may have inﬂuenced the type
of antithrombotic used and combination, such as dual an-
tiplatelet therapy, which is predominantly related to local
policies and individual patient factors. The focus of the
included studies varied widely and general outcome anal-
ysis was not uniformly applicable, and a number of poten-
tial biases warrant consideration. The data from non-
randomised studies are recognised to be exposed to bia-
ses and the outcome parameters may be inadequately
represented.11 Furthermore, selection biases must be
considered across the studies as doses of medication and
methodology of blood pressure control were not homoge-
nous. Treatment was largely decided by the treating
physician rather than from deﬁned treatment protocols. In
addition, the sample size of the only outcome with a result
close to signiﬁcance (i.e. death or disability, p ¼ 0.06) was
much smaller than that of other outcomes, as severalstudies did not provide data about disability. A further
limitation, with utilisation of the NOS, is the challenging
point of an under-appreciation of confounding factors,
presenting measurement challenges (e.g. the risk proﬁle of
patients, including blood pressure, family history).
This study has provided higher quality data using robust
statistical analysis on this patient group. Ideally, the devel-
opment of an international registry to log all the diagnostic
approaches, therapeutic treatments, and pre-deﬁned out-
comes will allow for a higher quality data to be collated on
this disease process and prognostic indicators. The Cervical
Artery Dissection and Ischaemic Stroke Patients (CADISP)
Group (CADISP, 2009) has initiated such a registry, pre-
liminary results of which have been included in this analysis.
Furthermore, a large randomised control trial comparing
anticoagulants with antiplatelets in CAD is important and
could solve the debate of whether to use immediate anti-
coagulation or not. A UK-based study is ongoing (CADISS,
2009) and preliminary results have been published.Conclusion
Until large registry or level 1 evidence is available, the
present data suggest that patients with CAD have equal
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Figure 6. (A) Comparison of AP and AC: Symptomatic intracranial haemorrhage. (B) Breakdown of comparison of AP and AC: Symptomatic
intracranial haemorrhage.
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Figure 7. (A) Comparison of AP and AC: Major extracranial haemorrhage. (B) Breakdown of comparison of AP and AC: Major extracranial
haemorrhage.
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Acute Extracranial Carotid Artery Dissections 155outcomes whether treated with antiplatelet agents or
anticoagulation, and, as such, treatment lies at the discre-
tion of the treating physician and on a case-by-case basis.
Evidence suggests that patients derive no greater beneﬁt
from one treatment over the other. The main limitation of
this analysis is the gap in the literature for randomised
controlled trials and, therefore, the completion of such
trials is warranted.CONFLICT OF INTEREST
None.FUNDING
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Supplementary data related to this chapter can be found at
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